Summary of Clinical Features and Laboratory Results in Patients with Positive Intraocular

Summary of Clinical features and Laboratory Results in Patients with Positive Intraocular Test (16 Toxoplasma, 6 Herpesviridae related).

Laboratory Results Case No/ age (years) Immune status Duration of symptoms Intraocular inflammation Clinical findings/site of PCR analysis Goldmann Witmer coefficient/ before intraocular AC retinal necrosis/ area of Serology: IgM Toxo if present, IgG Toxo sampling chorioretinitis Pathogen Toxoplasma gondii 1/ 35 Active C Hepatitis (IS) 4 M P Panuveitis, nasal, focal/ Toxo Pos Toxo Neg 6DP PCR VZV + VZV Pos/ coeff 2.19 IgM Toxo+

2/ 14 - 7ds P Panuveitis, , Vascularitis, Toxo Pos Toxo Neg hyalitis +, papilloedema/ HSV Pos/ coeff 3.4 ST, focal peripheral/ 4DP IgM-

3/ 72 Systemic corticotherapy 2 M P Panuveitis, hyalitis 3+, Toxo Pos Toxo Pos/ 2.9 Prednisolone 10mg/d focal, post pole / NC

4/ 68 - 21ds P Panuveitis, hyalite nil, Toxo Pos Toxo Pos/ 3.9 Vasculitis/ nasal, focal/ IgM Toxo+ 1/2 DP 5/ 24 - <7ds P Panuveitis, focal, ST/ Toxo Pos Toxo Neg NC IgM Toxo+ 6/59 - 7ds P Tyndall ½+, focal post Toxo Pos Toxo Pos/ 2.26 pole /NC IgM Toxo+

7/59 Bone marrow 3M P Tyndall+, hyalitis2+/ Toxo Pos Toxo Pos/ 4.59 transplantation, focal, nasal/ >3DP IgG 300 neutropenia (IS) 8/51 - 48h P Panuveitis granul, old sup Toxo Pos Toxo Neg ATCD 1995 lesions, hyalitis++/ 2DP IgG 44 9/37 - 21ds P Panuveitis, , hyalitis+++, Toxo Pos Toxo Pos/ 2.4 1 old scar/ sup focal, / 1 IgG 87 DP 10/35 - 1 M P Panuveitis, sup focal/ 7 Toxo Pos Toxo Pos/ 5 DP HSV Pos/ coff 2.5 11/12 - 19ds N hyalitis+, vasculitis/ ST Toxo Pos Toxo Pos/ 10.14 focal/ 3DP IgG 82.5

12/ 67 - 1 M N papillitis vasculitis, Toxo Pos Toxo Pos/ 3.27 hyalitis+++, tyndall++/ IgG 82.5 focal, scar/ 4DP 13/ 25 - 6 weeks N hyalitis++ papillitis/ Toxo Pos Toxo Pos/ 7.85 focal, post pole scar/ 3DP IgG 41.3

14/ 18 - 7 ds N Papillitis , hyalitis nil Toxo Pos Toxo Pos/ 3.08 Vasculitis, Neuroretinitis IgG 165

15/ 58 - 2 M N Tyndall 0, hyalitis 2+/ Toxo Pos Toxo Pos/ 9,7 sup, focal/ 3 DP 16/18 - 21 ds N Tyndall nil/ ST lesion, NP Toxo Pos/ 24.78 scars/ 1 DP 17/ 20 - 15 ds N vasculitis papillitis/ ST, NP Toxo Pos/ 8.45 focal, scar /2DP 18/ 59 - 6 ds N Hyalitis ½+/ multifocal NP Toxo Pos/ 11.3 focal IT, scars/ 1DP IgG 330 19/ 33 - 5 ds P Panuveitis granul, Toxo neg Toxo Pos Hyalitis 3+/ focal, IT 5.65 2DP IgG 37.5 20/ 47 - 15 ds P Panuveitis granul, Toxo Neg Toxo Pos / 2.19 Hyalitis 3+, /post pole IgG300 lesion/ 1DP 21/ 62 15 ds P Panuveitis non granul/ Toxo Neg Toxo Pos /2.45 ST, scars/ 1DP IgG 150 22/ 29 - 10 ds P Panuveitis, papillitis/ NP Toxo Pos / 12.23 focal, scars, Neuroretinitis/ 0 23/ 58 - 15 M N Scar, ERM post toxo/ 0 NP Toxo Pos / 24

24/ 30 - 7 ds N Multifocal, SN /1/6 DP Toxo Neg Toxo Pos /6

Herpes Virus 25/ 63 Breast cancer 1 M Retinitis CMV Pos CMV Pos/ 2 (chemotherapy) 26/ 37 HIV infection 24h Retinitis CMV Pos Viral neg/ IgG CMV 188

27/ 52 HIV infection 8 ds PORN Retinitis CMV Pos Viral neg 28/ 49 - 4 ds ARN HSV1 Pos Viral Neg

29/ 25 10 wks ARN HSV2 Pos HSV2 Pos 29

30/ 30 - 7ds ARN VZV Pos VZV Pos/ 34

P, present; A, absent; Neg, negative; Toxo, toxoplasmosis; IT, immusuppressive therapy or systemic corticosteroid; AC, anterior chamber inflammation; granul/ granulomateous; VC: viral charge, ds: days; M: months; wks: weeks, ARN: acute retinal necrosis; Pos: positive; Neg: negative; NP: not performed. IT: inferotemporal; ST: superotemporal; post pole: posterior pole.